全文获取类型
收费全文 | 833篇 |
免费 | 64篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 44篇 |
妇产科学 | 13篇 |
基础医学 | 117篇 |
口腔科学 | 31篇 |
临床医学 | 55篇 |
内科学 | 188篇 |
皮肤病学 | 17篇 |
神经病学 | 37篇 |
特种医学 | 144篇 |
外国民族医学 | 1篇 |
外科学 | 47篇 |
综合类 | 50篇 |
预防医学 | 41篇 |
眼科学 | 5篇 |
药学 | 40篇 |
中国医学 | 4篇 |
肿瘤学 | 66篇 |
出版年
2023年 | 2篇 |
2022年 | 2篇 |
2021年 | 8篇 |
2020年 | 7篇 |
2019年 | 8篇 |
2018年 | 20篇 |
2017年 | 14篇 |
2016年 | 15篇 |
2015年 | 18篇 |
2014年 | 21篇 |
2013年 | 37篇 |
2012年 | 35篇 |
2011年 | 26篇 |
2010年 | 44篇 |
2009年 | 47篇 |
2008年 | 27篇 |
2007年 | 27篇 |
2006年 | 15篇 |
2005年 | 24篇 |
2004年 | 15篇 |
2003年 | 17篇 |
2002年 | 18篇 |
2001年 | 17篇 |
2000年 | 11篇 |
1999年 | 18篇 |
1998年 | 37篇 |
1997年 | 36篇 |
1996年 | 39篇 |
1995年 | 38篇 |
1994年 | 25篇 |
1993年 | 21篇 |
1992年 | 7篇 |
1991年 | 6篇 |
1990年 | 16篇 |
1989年 | 16篇 |
1988年 | 18篇 |
1987年 | 10篇 |
1986年 | 16篇 |
1985年 | 12篇 |
1984年 | 17篇 |
1983年 | 18篇 |
1982年 | 14篇 |
1981年 | 14篇 |
1980年 | 15篇 |
1979年 | 5篇 |
1978年 | 8篇 |
1977年 | 2篇 |
1976年 | 8篇 |
1975年 | 5篇 |
1949年 | 1篇 |
排序方式: 共有901条查询结果,搜索用时 15 毫秒
101.
Successful conception and pregnancy in p‐ANCA‐associated vasculitis in course of treatment with immunosuppressive drugs and renal replacement therapy 下载免费PDF全文
102.
103.
Arianna Giacomini Sara Matarazzo Katiuscia Pagano Laura Ragona Sara Rezzola Michela Corsini Emanuela Di Salle Marco Presta Roberto Ronca 《Oncotarget》2015,6(15):13790-13802
Fibroblast growth factor-8b (FGF8b) affects the epithelial/stromal compartments of steroid hormone-regulated tumors by exerting an autocrine activity on cancer cells and a paracrine pro-angiogenic function, thus contributing to tumor progression. The FGF8b/FGF receptor (FGFR) system may therefore represent a target for the treatment of steroid hormone-regulated tumors. The soluble pattern recognition receptor long pentraxin-3 (PTX3) binds various FGFs, including FGF2 and FGF8b, thus inhibiting the angiogenic and tumorigenic activity of androgen-regulated tumor cells. Nevertheless, the complex/proteinaceous structure of PTX3 hampers its pharmacological exploitation. In this context, the acetylated pentapeptide Ac-ARPCA-NH2 (ARPCA), corresponding to the N-terminal amino acid sequence PTX3(100-104), was identified as a minimal FGF2-binding peptide able to antagonize the biological activity of FGF2. Here, we demonstrate that ARPCA binds FGF8b and inhibits its capacity to form FGFR1-mediated ternary complexes with heparan sulphate proteoglycans. As a FGF8b antagonist, ARPCA inhibits FGFR1 activation and signalling in endothelial cells, hampering the angiogenic activity exerted in vitro and in vivo by FGF8b. Also, ARPCA suppresses the angiogenic and tumorigenic potential of prototypic androgen/FGF8b-dependent Shionogi 115 mammary carcinoma cells and of androgen/FGF8b/FGF2-dependent TRAMP-C2 prostate cancer cells. In conclusion, ARPCA represents a novel FGF8b antagonist with translational implications for the therapy of steroid hormone-regulated tumors. 相似文献
104.
105.
106.
High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of vascular endothelium 总被引:3,自引:1,他引:3
An important biologic function of high-molecular-weight kininogen (HK) is to deliver bradykinin (BK) to its cellular receptors. Internalization and degradation of HK may provide a mechanism by which endothelial cells modulate the production of BK and control its activities. Therefore, we investigated the binding and subsequent distribution of biotinylated-HK (biotin-HK) associated with human umbilical vein endothelial cells (HUVEC). HUVEC bound 3 to 4 times more HK and with greater avidity at 1 to 3 hours at 37 degrees C than at 4 degrees C (Bmax = 1.0 +/- 0.02 x 10(7) molecules/cell, kd = 7 +/- 3 nmol/L v Bmax = 2.6 +/- 0.2 x 10(6) molecules/cell, kd = 46 +/- 8 nmol/L). However, there was no evidence that the difference was caused by internalization of HK at the higher temperature. First, the same amount of biotin-HK was associated with nonpermeabilized and permeabilized HUVEC using buffers containing 20 to 50 mumol/L zinc ion in the absence or presence of 2 mmol/L calcium ion. Second, binding of biotin-HK to HUVEC was approximately 92% reversible at 1 hour when the cells were maintained at both 37 degrees C and 4 degrees C. Third, neither chloroquine nor primaquine altered the amount of biotin-HK bound to HUVEC. Fourth, biotin-HK bound to HUVEC was almost completely removed by pronase. Fifth, the nonpermeable dye, crystal violet, almost completely quenched the fluorescence signal emitted by HUVEC-associated fluorescein isothiocyanate (FITC) HK. Finally, the localization of HUVEC-bound FITC-HK was restricted to the membrane as shown by laser scanning confocal microscopy. The expression of HK binding sites had an absolute requirement for metabolic energy, but was not dependent on new protein synthesis. Membrane-bound HK contributed to the anticoagulant nature of endothelial cells by blocking human alpha-thrombin binding and its resultant induction of prostacyclin formation. These studies indicate that HK is not internalized by HUVEC, but remains primarily on cell surfaces to be accessible for BK liberation and to modulate the binding and actions of alpha-thrombin. 相似文献
107.
Role of light chain variable region in myeloma with light chain deposition disease: evidence from an experimental model 总被引:4,自引:2,他引:4
Khamlichi AA; Rocca A; Touchard G; Aucouturier P; Preud'homme JL; Cogne M 《Blood》1995,86(10):3655-3659
Light chain deposition disease (LCDD) results from a propensity of some human monoclonal L chains to form tissue deposits. We designed an experimental model for in vivo expression of human kappa L chain sequences in mice and compared a somatically mutated LCDD chain with a closely related control kappa chain, both encoded by the unique V kappa IV gene. Mice secreting the LCDD chain but not those producing the control chain showed deposits with a distribution similar to that observed in patients. These data show that discrete changes in V region sequences can play a major role in tissue deposition of human L chains. 相似文献
108.
The Ig heavy chain (IgH) gene was used as a marker to investigate clonal succession and the origin of the neoplastic cell in multiple myeloma. The polymerase chain reaction (PCR) was used to amplify a section of the rearranged IgH gene at diagnosis and at progression in 21 patients who had exhibited a plateau phase. A monoclonal PCR product was seen for 16 of the patients and the product present at progression was of the same molecular weight as that at diagnosis. This finding suggests that the IgH rearrangement present at diagnosis and progression was the same. This was confirmed by sequencing the IgH gene in 10 patients. The IgH genes were found to be hypermutated at diagnosis, but no further hypermutation occurred during the course of the disease. The results provide evidence that the neoplastic cell in myeloma may originate as a memory B cell, plasmablast, or plasma cell, and suggest that progression beyond the plateau phase is not caused by clonal succession. 相似文献
109.
Heterogeneity of breakpoints of 11q23 rearrangements in hematologic malignancies identified with fluorescence in situ hybridization 总被引:3,自引:0,他引:3
Kobayashi H; Espinosa R d; Thirman MJ; Gill HJ; Fernald AA; Diaz MO; Le Beau MM; Rowley JD 《Blood》1993,82(2):547-551
Twenty-four patients whose cells contained a variety of 11q23 rearrangements, including translocations, insertions, and an inversion, were studied using fluorescence in situ hybridization with cosmid, phage, and plasmid probes mapped to 11q22-24. In 17 patients, the breakpoints of the common 11q23 translocations involving chromosomes 4, 6, 9, and 19 as well as some uncommon translocations involving 3q23, 17q25, 10p11, and an insertion 10;11 were all located in the breakpoint cluster region of the MLL gene, regardless of age, phenotype of disease, or involvement of a third chromosome. The breakpoints in 11q23 in the other 7 patients with a t(7;11)(p15;q23), inv(11)(p11q23), t(4;11)(q23;q23), der(5)t(5;11)(q13;q23), ins(10;11)(p11;q23q24), t(11;14)(q23;q11), or t(11;18;11) (p15;q21;q23) were located either centromeric to CD3D or telomeric to THY1. Thus, although most 11q23 rearrangements, involve the same breakpoint cluster region of MLL, there is heterogeneity in the breakpoint in some of the rare rearrangements. 相似文献
110.
Imtiaz M. Nawaz Paola Chiodelli Sara Rezzola Giuseppe Paganini Michela Corsini Alessio Lodola Alessio Di Ianni Marco Mor Marco Presta 《Angiogenesis》2018,21(1):47-59
The peptides N-tert-butyloxycarbonyl-Phe-Leu-Phe-Leu-Phe (BOC2) and BOC-Met-Leu-Phe (BOC1) are widely used antagonists of formyl peptide receptors (FPRs), BOC2 acting as an FPR1/FPR2 antagonist whereas BOC1 inhibits FPR1 only. Extensive investigations have been performed by using these FPR antagonists as a tool to assess the role of FPRs in physiological and pathological conditions. Based on previous observations from our laboratory, we assessed the possibility that BOC2 may exert also a direct inhibitory effect on the angiogenic activity of vascular endothelial growth factor-A (VEGF-A). Our data demonstrate that BOC2, but not BOC1, inhibits the angiogenic activity of heparin-binding VEGF-A165 with no effect on the activity of the non-heparin-binding VEGF-A121 isoform. Endothelial cell-based bioassays, surface plasmon resonance analysis, and computer modeling indicate that BOC2 may interact with the heparin-binding domain of VEGF-A165, thus competing for heparin interaction and preventing the binding of VEGF-A165 to tyrosine kinase receptor VEGFR2, its phosphorylation and downstream signaling. In addition, BOC2 inhibits the interaction of a variety of heparin-binding angiogenic growth factors with heparin, including fibroblast growth factor 2 (FGF2) whose angiogenic activity is blocked by the compound. Accordingly, BOC2 suppresses the angiogenic potential of human tumor cell lines that co-express VEGF-A and FGF2. Thus, BOC2 appears to act as a novel multi-heparin-binding growth factor antagonist. These findings caution about the interpretation of FPR-focusing experimental data obtained with this compound and set the basis for the design of novel BOC2-derived, FPR independent multi-target angiogenesis inhibitors. 相似文献